GATC Health Publishes a Digital Twin Framework for Therapeutic Development

New paper formalizes the multi-scale architecture behind Operon™ and advances GATC’s position in AI-native drug development

Irvine, CA — May 08, 2026 — GATC Health has announced the publication of “A Multi-Scale, Evidence-Orchestrated Digital Twin Architecture for Therapeutic Development: A Systems-Theoretic Framework,” now published in Advances in Clinical and Medical Research. Authors include GATC’s Ian Jenkins, Vaishnavi Narayan, Waldemar Lernhardt, Valentina Savich, Eric Mathur, Robert Tinder, Jayson Uffens, and corresponding author Jonathan RT Lakey, plus Krista Casazza.

The publication sets out a formal digital twin architecture for therapeutic development, grounded in multiomic integration, distributed probabilistic modeling, constraint-based reasoning, reinforcement learning, neural inference, and structured evidence synthesis. In practical terms, it describes how Operon is built to model biology across molecular, cellular, tissue, and organism levels, simulate intervention scenarios, propagate uncertainty, and support higher-quality development decisions before capital and time are committed in the clinic.

The industry is moving past narrow AI tools that identify patterns after the fact towards systems that can reason across biology, evaluate counterfactuals, and forecast how therapies are likely to perform under real-world development constraints. This paper positions digital twins not as a futuristic concept, but as a serious computational framework for candidate selection, dosing strategy, trial design, enrichment logic, and risk–benefit assessment.

Just as importantly, the paper emphasizes traceability, evidence orchestration, and validation. The framework is designed not as a black box, but as a structured scientific computing system that integrates heterogeneous data into interpretable outputs for expert review. The authors also report strong concordance under blinded evaluation conditions, reinforcing the paper’s core argument that digital twin systems in drug development must be judged by scientific rigor.

GATC is currently using Operon to deliver actionable guidance to biopharma discovery and development teams, pipeline prioritization and capital allocation insights to boards and executive teams, and predictive analysis of drug candidates for the world’s first clinical trial financing insurance by MCI, Acrisure and Lloyd’s.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment firms, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform, Operon™, is generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit gatchealth.com.